<DOC>
	<DOC>NCT03034096</DOC>
	<brief_summary>This is a large pragmatic multicenter trial comparing maintenance of general anesthesia with total intravenous anesthesia using propofol versus volatile agent (sevoflurane, isoflurane, or desflurane) during cancer surgery. The primary endpoint is all-cause mortality.</brief_summary>
	<brief_title>General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial</brief_title>
	<detailed_description />
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Anesthetics, General</mesh_term>
	<criteria>Patients with known or suspected cancer and scheduled to undergo any of the following oncologic surgical procedures: Lobectomy or pneumonectomy Esophagectomy Radical (total) cystectomy Pancreatectomy Partial hepatectomy Hyperthermic intraperitoneal chemotherapy (HIPEC) Gastrectomy (subtotal or total) Cholecystectomy or bile duct resection Age less than 18 years American Society of Anesthesiologist Class 5 Projected life expectancy less than 30 days Known or suspected hypersensitivity to either propofol, e.g. egg or soy allergy, or volatile general anesthetic agents Known or suspected history of malignant hyperthermia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>